leadf
logo-loader
RNS
viewHemoGenyx Pharmaceuticals

Hemogenyx Pharma Plc - Further re. Grant of Options

RNS Number : 7514Z
Hemogenyx Pharmaceuticals PLC
22 September 2020
 

22 September 2020

 

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

 

Further re. Grant of Options

 

On 21 August 2020, the Company announced that the Directors had granted the Company's co-founder and CEO Dr Vladislav Sandler options over a total of 5,000,000 ordinary shares of 1p each in the capital of the Company ("Share Options").  The Directors have now resolved to adjust the exercise price of the Share Options to 9p to reflect the Company's share price at the time of the grant.  All other details regarding the grant of the Share Options remain the same.

 

Enquiries:

 

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

[email protected]

Peter Redmond, Director

[email protected]





SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev







Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow



 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA"):

1.

Details of PDMR/person closely associated with them

a)

Name

Dr Vladislav Sandler

b)

Position/status

CEO, Executive Director

c)

Initial notification/
amendment

Amendment to prior notification no. 00117904

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc
Identification code GB00BYX3WZ24

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.09

5,000,000

 

 

d)

Aggregated information

-     Aggregated volume

-     Price

Price(s)

Volume(s)

N/A - variable

5,000,000

e)

Date of the transaction

20/08/2020

f)

Place of the transaction

Outside of a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPPUBCBUPUGGP

Quick facts: HemoGenyx Pharmaceuticals

Price: 9.1

Market: LSE
Market Cap: £39.46 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

4 min read